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OBJECTIVES: Traditional antidiabetic therapies often fail to
maintain glycaemic control. In this retrospective analysis using a
large, national commercial health care claims database, we
describe baseline characteristics, comorbidities and concomitant
therapies in patients prescribed exenatide in the ﬁrst 13 months
following FDA approval. METHODS: A total of 3578 patients
were identiﬁed who had a prescription claim for exenatide
between May 1, 2005 and May 31, 2006, at least 12 months
pre-index eligibility (ﬁrst claim deﬁned as index date), and were
at least 18 years old. Of these, 3454 patients (96.5%) had
a pre-index diagnosis for type 2 diabetes based on diagnosis
code and/or medication. RESULTS: Mean (SD) age was
54.2  10.0 years; 49.7% were female and 12.7% were at least
65 years of age. Baseline HbA1C values obtained within 100
days before the index date were available for 340 patients
(mean  SD = 8.0  1.6%). The most common comorbidities
associated with diabetes reported in the 12 months prior to the
index date were dyslipidaemia (87.7%), hypertension (64.3%),
and other cardiovascular disease (27.7%). Most patients analy-
sed (94.2%) were treated with at least one other antidiabetic
medication at baseline; 22.1% with one drug, 34.3% with 2
drugs, and 37.8% with at least 3 drugs. Metformin was the most
common baseline therapy (74.5%), followed by thiazolidinedi-
ones (50.6%), sulphonylureas (49.0%), and insulin (29.7%).
CONCLUSION: This study provides the ﬁrst nonclinical trial
population analysis of the baseline HbA1C, demographics,
comorbidities and concomitant diabetes therapies in patients
initiated on exenatide. The mean baseline HbA1C indicates that
these patients were not achieving glycaemic control as deﬁned by
current guidelines, supporting the notion that diabetes remains a
difﬁcult disease in which to achieve therapeutic goals. In the ﬁrst
13 months since US FDA approval, exenatide was predominantly
prescribed to patients with type 2 diabetes who were failing to
achieve glycaemic control with prior antidiabetic therapy.
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OBJECTIVES: In clinical trials, exenatide improved glycaemic
control and was associated with weight reduction and improve-
ment in several cardiovascular risk factors. In this retrospective
analysis using a large, national commercial health care claims
database, we describe changes in concomitant diabetes therapies
in patients with type 2 diabetes who had a prescription claim for
exenatide in the ﬁrst 13 months following US FDA approval.
METHODS: A total of 1637 patients who were at least 18 years
old, had type 2 diabetes, had an initial (index) claim for
exenatide between May 1, 2005 and May 31, 2006, and had 12
months of pre index and 6 months of post index eligibility were
included. Baseline diabetes therapies were deﬁned as prescrip-
tions ﬁlled 100 days pre index through 15 days post index;
post-index therapies were deﬁned as any prescriptions ﬁlled at
least 16 days to 180 days post index. RESULTS: In the post-
index period, the number of patients with prescription claims for
metformin, thiazolidinediones, and sulphonylureas decreased
by 14.3% (P < 0.0001), 16.0% (P < 0.0001), and 25.0%
(P < 0.0001), respectively. Patients with prescription claims for
both metformin and a sulphonylurea declined by 25.9%
(P < 0.0001) and patients with prescriptions claims for the com-
bination of metformin, a thiazolidinedione, and a sulphonylurea
decreased by 40.1% (P < 0.0001). The percentage of patients
with prescription claims for insulin was similar between baseline
and post-index periods. CONCLUSION: This study provides the
ﬁrst nonclinical trial population analysis of changes in concomi-
tant diabetes therapies following initiation of exenatide therapy,
and demonstrates that exenatide initiation was associated with a
signiﬁcant reduction in prescription claims for other diabetes
therapies.
DIABETES—Methods and Concepts
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OBJECTIVES: Surrogates are valid endpoints, when they could
reliably predict the causal clinical beneﬁts and harms of a
therapy on the clinical endpoint. The importance of beta-cell
dysfunction in patients with type 2 diabetes has been increas-
ingly recognized as the decrease in endogenous insulin secretion
makes drug therapy difﬁcult. Several new antidiabetic drugs
focus on an improvement of beta-cell activity as a tool for
therapeutic treatment. In type 1 diabetes even residual
C-peptide secretion is associated with reduction of diabetes
related complications. A preservation of beta-cell function
might be associated with improved outcomes. The objective of
this project is to evaluate the relationship between patient-
relevant endpoints and the surrogate beta-cell activity.
METHODS: We systematically searched the literature data-
bases of the Centre of Reviews and Dissemination, MEDLINE
and EMBASE for relevant publications. All systematic reviews,
Health Technology Assessments and Randomized Controlled
Trials (RCT) published 1990–2007 were included. Due to the
small number of publications that assessed clinical endpoints
modulated by beta-cell activity in type 2 diabetic Caucasians,
cohort studies were also recognized. Patient-relevant outcomes
were deﬁned according to the German Institute for Quality and
Efﬁciency in Health Care. Beta-cell activity was measured by
C-peptide, fasting insulin excretion or HOMA. Only trials were
included not aimed to compare therapeutic interventions to
preclude bias of bypass pathways to the clinical endpoint.
RESULTS: No publications on high level of evidence were iden-
tiﬁed. Study length of the 17 cohort studies was between 4–14
years. Three studies showed a signiﬁcant association of beta-
cell activity with all-cause mortality and three of four studies
showed a signiﬁcant association with cardiovascular mortality.
For microvasular and macrovascular endpoints heterogenous
results were reported. CONCLUSION: There is some evidence
for an association between beta-cell activity and all-cause and
cardiovascular mortality. Validity should to be further evalu-
ated in RCTs.
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